Please note: Product illustrations may slightly vary. If you have any questions about a product or service, we are happy to help.
Heel Engystol Bundle (Engystol N, Gripp-Heel and Euphorbium Nasal Spray)
Looking to purchase this product?
Since this is an unlicensed medicinal product, we’ll need to confirm it’s right for you. After purchase, you’ll receive a quick 2-minute questionnaire via email. Once our pharmacist reviews it, we’ll ship your order.
Unsure about a product or service?
Feel free to contact us by email or call us on +44 203 771 9927
Prefer to just message?
Contact us via WhatsApp: +4474 8338 0720
The Wellness Pharmacy
43 Shad Thames
SE1 2NJ, London, UK
Please note: Product illustrations may slightly vary. If you have any questions about a product or service, we are happy to help.
-
The anti-viral activity of Engystol and Gripp-Heel have been studied in-vitro and the findings were that the two ultra-low-dose combination medications, Engystol® and Gripp-Heel®, have documented efficacy for the treatment of the respiratory infections and the conclusions were that Engystol® and Gripp-Heel® inhibited the replication of a variety of respiratory viruses. Additionally, we showed that pre-incubation affects the magnitude of the inhibitory effect differently for the various tested viruses. Both medications stimulate type 1 IFN release in different cell systems which suggests that their antiviral activity may be mediated possibly via modulation of the antiviral type 1 IFN host response.
Euphorbium Compositum nasal spray was also studied, and the result was that the analysis of virus production after treatment of the infected cells with the remedy showed an antiviral activity of Euphorbium compositum SN against RSV and HSV-1. In addition, an antiviral effect against influenza A virus and HRV, though minimal, was, also noted. Analyses of the plant-derived components of Euphorbium compositum SN, e.g. Euphorbium resinifera, Pulsatilla pratensis and Luffa operculata for their antiviral activity revealed a clear activity of Euphorbium resinifera and Pulsatilla pratensis against RSV.
The anti-viral activity of Engystol and Gripp-Heel have been studied in-vitro and the findings were that the two ultra-low-dose combination medications, Engystol® and Gripp-Heel®, have documented efficacy for the treatment of the respiratory infections and the conclusions were that Engystol® and Gripp-Heel® inhibited the replication of a variety of respiratory viruses. Additionally, we showed that pre-incubation affects the magnitude of the inhibitory effect differently for the various tested viruses. Both medications stimulate type 1 IFN release in different cell systems which suggests that their antiviral activity may be mediated possibly via modulation of the antiviral type 1 IFN host response.
Euphorbium Compositum nasal spray was also studied, and the result was that the analysis of virus production after treatment of the infected cells with the remedy showed an antiviral activity of Euphorbium compositum SN against RSV and HSV-1. In addition, an antiviral effect against influenza A virus and HRV, though minimal, was, also noted. Analyses of the plant-derived components of Euphorbium compositum SN, e.g. Euphorbium resinifera, Pulsatilla pratensis and Luffa operculata for their antiviral activity revealed a clear activity of Euphorbium resinifera and Pulsatilla pratensis against RSV.
